Vetoquinol SA (LON:0O1O)

London flag London · Delayed Price · Currency is GBP · Price in EUR
78.90
-0.60 (-0.75%)
Mar 20, 2026, 3:51 PM GMT
Market Cap808.81M +13.8%
Revenue (ttm)456.36M -0.9%
Net Income51.39M +27.2%
EPS4.37 +27.9%
Shares Outn/a
PE Ratio15.74
Forward PE15.36
Dividend0.75 (0.97%)
Ex-Dividend DateJun 4, 2025
Volume20
Average Volume23
Open79.60
Previous Close79.50
Day's Range78.90 - 79.70
52-Week Range69.20 - 91.20
Beta0.99
RSI39.55
Earnings DateMar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1933
Employees 2,497
Stock Exchange London Stock Exchange
Ticker Symbol 0O1O
Full Company Profile

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial numbers in EUR Financial Statements